Repligen (RGEN) Set to Post Quarterly Earnings on Tuesday

Key Points

• Repligen is expected to report Q3 2026 results before market open on October 27. Analysts forecast earnings of $0.4628 per share and revenue of $206.71 million, compared with the company’s full-year EPS guidance of $2.03–$2.09.
• The company exceeded expectations in its most recent quarter, reporting $0.54 EPS and $204.13 million in revenue. Revenue increased 11.9% year over year.
• Wall Street maintains a generally positive view, with a consensus rating of “Moderate Buy” and an average price target of $175.71, while Repligen shares recently traded at $176.43 and carried a high valuation with a P/E ratio of 89.05.

Repligen (NASDAQ:RGEN - Get Free Report) is expected to announce its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect the company to announce earnings of $0.4628 per share and revenue of $206.71 million for the quarter. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Investors may review the information on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:00 AM ET.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%. The company had revenue of $204.13 million for the quarter, compared to analysts' expectations of $201.59 million. During the same period in the previous year, the business posted $0.26 earnings per share. The business's quarterly revenue was up 11.9% compared to the same quarter last year. On average, analysts expect Repligen to post $2.06 EPS for the current fiscal year and $2.59 EPS for the next fiscal year.

Repligen Stock Performance

Repligen stock opened at $176.43 on Tuesday. The business has a 50 day moving average of $176.12 and a 200-day moving average of $146.17. Repligen has a 1 year low of $100.99 and a 1 year high of $198.87. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The company has a market capitalization of $9.96 billion, a P/E ratio of 89.05, a P/E/G ratio of 3.20 and a beta of 1.08.

Wall Street Analyst Weigh In

Several research firms recently commented on RGEN. UBS Group reiterated a "buy" rating on shares of Repligen in a research report on Tuesday, September 29th. Evercore reissued an "outperform" rating and set a $160.00 target price on shares of Repligen in a report on Monday, July 6th. JPMorgan Chase & Co. upped their price target on shares of Repligen from $165.00 to $175.00 and gave the company an "overweight" rating in a research report on Wednesday, July 29th. Weiss Ratings raised shares of Repligen from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, October 8th. Finally, Barclays raised their price target on shares of Repligen from $175.00 to $225.00 and gave the company an "overweight" rating in a research note on Wednesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $175.71.

Repligen Company Profile

Repligen Corporation NASDAQ: RGEN develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company's offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.